Big Pharma Explores New Frontier Of Lung Cancer Immunotherapy
Executive Summary
Lung cancer wasn’t viewed traditionally as a tumor that would respond to immunotherapy. But with checkpoint inhibitor data looking promising, big pharma is diving in and prioritizing the disease, reeled in by the large patient population and high unmet need.
You may also be interested in...
Latest PD-L1 Lung Cancer Data Increases Debate On Biomarker
Data and filing announcements for Bristol and Merck’s PD-1 inhibitors in lung cancer put PD-L1 inhibitor developers in hot seat and create more debate about strategy and practicality of the PD-L1 biomarker.
Industry, Cancer Groups Draft Blueprint For PD-1 Companion Dx Approvals
Drug and test firms want to standardize FDA's companion diagnostic assessments for the high-profile new class of PD-1/PD-LI immunotherapy cancer drugs, an issue discussed at a recent FDA/cancer groups meeting.
Opdivo Lung Cancer Approval Holds Lessons For Competitors
Bristol is required to run a new study assessing the risk for pneumonitis, but analysts do not see the adverse event as a competitive threat. FDA showed significant flexibility with broad, fast approval, but Opdivo’s survival advantage may raise the bar for the rest of the class.